Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1- oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP- specific phosphodiesterase (PDE5)

Biochemical Pharmacology

Volumn 60, Issue 9, 2000, Pages 1333-1341

  Kotera, Jun ^a   Fujishige, Kotomi ^a   Michibata, Hideo ^a   Yuasa, Keizo ^a   Kubo, Akira ^a   Nakamura, Yoshinori ^a   Omori, Kenji ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Canine; cGMP; Inhibitor; Isozyme; Phosphodiesterase; Vascular smooth muscle cells

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; CYCLIC GMP PHOSPHODIESTERASE; GUANYLATE CYCLASE; METHYL 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINE CARBOXYLATE SULFATE; METHYL 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLATE SULFATE; NATRIURETIC PEPTIDE TYPE C; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ALTERNATIVE SPLICING; ANIMALS; CELLS, CULTURED; CYCLIC AMP; CYCLIC GMP; DOGS; ENZYME INHIBITORS; ISOENZYMES; ISOQUINOLINES; KINETICS; MALE; MUSCLE, SMOOTH, VASCULAR; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034333326     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00457-3     Document Type: Article

References (46)

1. Kukovetz W.R., Holzmann S., Wurm A., Poch G. Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 310:1979;129-138.
2. Ignarro L.J., Kadowits P.J. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol. 25:1985;171-191.
3. Martin W., Furchgott R.F., Villani G.M., Jothianandan O. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther. 237:1986;539-547.
4. Shibuki K., Okada D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature. 349:1991;326-328.
5. Bredt D.S., Snyder S.H. Nitric oxide, a novel neuronal messenger. Neuron. 8:1992;3-11.
6. Snyder S.H. Nitric oxide First in a new class of neurotransmitters . Science. 257:1992;494-496.
7. Zhou M., Hu Y., Schultz C., Kandel E.R., Hawkins R.D. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature. 368:1994;635-639.
8. Currie M.G., Fok K.F., Kato J., Moore R.J., Hamra F.K., Duffin K.L., Smith C.E. Guanylin, An endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA. 89:1992;947-951.
9. Iwatsuki K., Horiuchi A., Ren L.M., Chiba S. Effects of KRN2391, a novel vasodilator, on pancreatic exocrine secretion in anesthetized dogs. Eur J Pharmacol. 249:1993;19-24.
10. Nisoli E., Clementi E., Tonello C., Sciorati C., Briscini L., Carruba M.O. Effect of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary culture. Br J Pharmacol. 125:1998;888-894.
11. Ignarro L.J., Harbison R.G., Wood K.S., Kadowitz P.J. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein Stimulation by acetylcholine, bradykinin and arachidonic acid . J Pharmacol Exp Ther. 237:1986;893-899.
12. Ignarro L.J. Endothelium-derived nitric oxide Actions and properties . FASEB J. 3:1989;31-36.
13. Waldman S.A., Rapoport R.M., Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem. 259:1984;14332-14334.
14. Chang M., Lowe D.G., Lewis M., Hellmiss R., Chen E., Goeddel D.V. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature. 341:1989;68-72.
15. Beavo J.A. Cyclic nucleotide phosphodiesterases Functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
16. Juilfs D.M., Soderling S.H., Burns F., Beavo J.A. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol. 135:1999;67-104.
17. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP. J Biol Chem. 274:1999;18438-18445.
18. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA and Phillips SC, Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97: 3702-3207, 2000.
19. Souness J.E., Brazdil R., Diocee B.K., Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 98:1989;725-734.
20. Saeki T., Saito I. Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. Biochem Pharmacol. 46:1993;833-839.
21. Miyahara M., Ito M., Itoh H., Shiraishi T., Isaka N., Konishi T., Nakano T. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta Characterization and the effects of E4021 . Eur J Pharmacol. 284:1995;25-33.
22. Lincoln T.M., Hall C.L., Park C.R., Corbin J.D. Guanosine 3′, 5′-cyclic monophosphate binding proteins in rat tissues. Proc Natl Acad Sci USA. 73:1976;2559-2563.
23. Hamet P., Coquil J.F. Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets. J Cyclic Nucleotide Res. 4:1978;281-290.
24. Coquil J.F., Brunelle G., Guédon J. Occurrence of the methylisobutylxanthine-stimulated cyclic GMP binding protein in various rat tissues. Biochem Biophys Res Commun. 127:1985;226-231.
25. Kotera J., Yanaka N., Fujishige K., Imai Y., Akatsuka H., Ishizuka T., Kawashima K., Omori K. Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal development. Eur J Biochem. 249:1997;434-442.
26. Yanaka N., Kotera J., Ohtsuka A., Akatsuka H., Imai Y., Michibata H., Fujishige K., Kawai E., Takebayashi S., Okumura K., Omori K. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase. Eur J Biochem. 255:1998;391-399.
27. Kotera J., Fujishige K., Akatsuka H., Imai Y., Yanaka N., Omori K. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem. 273:1998;26982-26990.
28. Kotera J., Fujishige K., Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem. 48:2000;685-693.
29. Kotera J., Fujishige K., Imai Y., Kawai K., Michibata H., Akatsuka H., Yanaka Y., Omori K. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur J Biochem. 262:1999;866-872.
30. Ahn H.S., Crim W., Romano M., Sybertz E., Pitts B. Effect of selective inhibitor on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 38:1989;3331-3339.
31. Hartell N.A. Inhibition of cGMP breakdown promotes the induction of cerebellar long-term depression. J Neurosci. 16:1996;2881-2890.
32. Saeki T., Adachi H., Takase Y., Yoshitake S., Souda S., Saito I. A selective type V phosphodiesterase inhibitor, E-4021, dilates porcine large coronary artery. J Pharmacol Exp Ther. 272:1995;825-831.
33. Cohen A.H., Hanson K., Morris K., Fouty B., McMurty I.F., Clarke W., Rodman D.M. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 97:1996;172-179.
34. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil, An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 8:1996;47-52.
35. Kodama K., Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertension rats. J Pharmacol Exp Ther. 290:1999;748-752.
36. Yamazaki A., Tatsumi M., Bitensky M.W. Purification of rod outer segment GTP-binding protein subunits and cGMP phosphodiesterase by single-step column chromatography. Methods Enzymol. 159:1988;702-710.
37. Thompson W.J., Terasaki W., Epstein P.M., Strada S.J. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res. 10:1979;69-92.
38. - cotransport in vascular smooth muscle cells. J Biol Chem. 261:1986;15461-15466.
39. Turko I.V., Ballard S.A., Francis S.H., Corbin J.D. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol. 56:1999;124-130.
40. Turko I.V., Francis S.H., Corbin J.D. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem. 273:1998;6460-6466.
41. Silver P.J., Hamel L.T., Perrone M.H., Bentley R.G., Bushover C.R., Evans D.B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol. 150:1988;85-94.
42. Francis S.H., Corbin J.D. Purification of cGMP-binding protein phosphodiesterase from rat lung. Methods Enzymol. 159:1988;722-729.
43. Thomas M.K., Francis S.H., Corbin J.D. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem. 265:1990;14964-14970.
44. Wallis R.M., Corbin J.D., Francis S.H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 83:1999;3C-12C.
45. Furuya M., Yoshida M., Hayashi Y., Ohnuma N., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 177:1991;927-931.
46. Ryvalkin S.D., Bornfeldt K.E., Sonnenburg W.K., Rybalkina I.G., Kwak K.S., Hanson K., Kreb E.G., Beavo J.A. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 100:1997;2611-2621.